Education
About Us
Working with TipRanks
Follow Us
NATCO Pharma Limited (IN:NATCOPHARM)
:NATCOPHARM
Paclitaxel, Nrc-2694-A
Carcinoma, Recurrent And/Or Metastatic Head And Neck Squamous Cell Carcinoma
Phase II
Active Not Recruiting
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Feb 08, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does NATCO Pharma Limited (NATCOPHARM) have in its pipeline
NATCOPHARM is currently developing the following drugs: Paclitaxel, Nrc-2694-A. These drug candidates are in various stages of clinical development as the company works toward FDA approval.